Product
Help
Pricing
About
Jobs
Log in
Get started
Author
Add to collection
Safa Can Efil
Observed names:
Efil, Safa Can,
S.C. Efil,
SAFA CAN EFİL,
Safa C. Efil,
Safa can Efil
Institutions:
Ankara Yıldırım Beyazıt University,
Ankara Bilkent City Hospital
Observed institutions:
Hacettepe University Hospital,
Sağlık Bilimleri Üniversitesi,
Ankara Yıldırım Beyazıt University,
Ankara Bilkent City Hospital,
Ankara Etlik City Hospital,
Hacettepe University
show all 6
ORCID:
0000-0001-9586-2858
Observed ORCID:
0000-0001-9586-2858
OpenAlex ID:
A5028291451
Prognostic and predictive value of tumor infiltrating lymphocytes in combination with systemic inflammatory markers in colon cancer
2023
·
Safa Can Efil
, Gunes Guner
, et al.
·
Clinics and Research in Hepatology and Gastroenterology
·
22
Efficacy and safety of G-CSF prophylaxis in patients with extensive-stage small cell lung cancer receiving chemoimmunotherapy
2024
·
Yusuf Ilhan
, Gokhan Ucar
, et al.
·
Expert Opinion on Pharmacotherapy
·
8
Correlation of PD-L1 and HIF-1 Alpha Expression with KRAS Mutation and Clinicopathological Parameters in Non-Small Cell Lung Cancer
2025
·
Seda Er Özilhan
, Safa Can Efil
, et al.
·
Current Issues in Molecular Biology
·
5
Health-related quality of life and psychosocial outcomes in long-term survivors treated with immune checkpoint inhibitors: a nationwide multicenter study
2025
·
Taha Koray Sahin
, Fatih Atalah
, et al.
·
Frontiers in Immunology
·
4
PDF
Real‐world effectiveness and safety of sacituzumab govitecan in patients with metastatic or unresectable locally advanced triple‐negative breast cancer: A multicenter study by the Turkish Oncology Group
2025
·
Salih Tunbekici
, Gokhan Sahin
, et al.
·
International Journal of Cancer
·
3
Synergistic prognostic effect of the renin‐angiotensin‐aldosterone system and immune‐checkpoint inhibition in advanced lung cancer: The SPERICIL study
2025
·
Safa Can Efil
, Sema Nur Ozsan Celebi
, et al.
·
International Journal of Cancer
·
3
The effect of dose reduction of CDK4/6 inhibitors on survival in postmenopausal HR+ HER2-negative metastatic breast cancer
2025
·
Furkan Ceylan
, Safa Can Efil
, et al.
·
Expert Review of Anticancer Therapy
·
3
Large Unstained Cells (LUC): A Novel Predictor of CDK4/6 Inhibitor Outcomes in HR+ HER2-Negative Metastatic Breast Cancer
2024
·
Furkan Ceylan
, Mirmehdi Mehdiyev
, et al.
·
Journal of Clinical Medicine
·
3
PDF
1875P Real-world evidence of ribociclib induced liver toxicity in patients with breast cancer: A multi-center experience
2024
·
O. Bas
, B.K. Inci
, et al.
·
Annals of Oncology
·
3
A current comprehensive role of immune-checkpoint inhibitors in resectable non-small cell lung cancer: A narrative review
2024
·
Safa Can Efil
, Burak Bilgin
, et al.
·
Journal of Oncology Pharmacy Practice
·
3
456P Prognostic and predictive value of tumor-infiltrating lymphocytes in combination with systemic inflammatory markers in colon cancer
2021
·
S.C. Efil
, G. Güner
, et al.
·
Annals of Oncology
·
3
Real-world evidence of ribociclib-induced hepatotoxicity in patients with breast cancer: a multi-center experience
2025
·
Onur Baş
, Bediz Kurt İnci
, et al.
·
BMC Cancer
·
2
PDF
Pretreatment HALP Score and Survival Outcomes in Patients with Metastatic Renal Cell Carcinoma Receiving First-Line Tyrosine Kinase Inhibitors: A Turkish Oncology Group Kidney Cancer Consortium (TKCC) Study
2026
·
Murat Günaltılı
, Hatice Bölek
, et al.
·
Cancers
·
1
Prognostic value of the glucose-to-lymphocyte ratio in surgically treated endometrial cancer: a retrospective cohort study
2026
·
Furkan Ceylan
, Serhat Sekmek
, et al.
·
Future Oncology
·
1
Durvalumab-Based First-Line Chemoimmunotherapy in Advanced Biliary Tract Cancer: Real-World Outcomes and Prognostic Factors—A Turkish Oncology Group Study
2025
·
Safa Can Efil
, Fatih Kus
, et al.
·
Cancers
·
1
PDF
2079eP The NLA score as a prognostic biomarker in advanced driver-negative NSCLC treated with immunotherapy-based strategies
2025
·
F. Ceylan
, S.C. Efil
, et al.
·
Annals of Oncology
·
1
Comparison of Frontline FOLFIRINOX with Fluorouracil-Based and Gemcitabine-Based Chemotherapies in Metastatic Ampullary Adenocarcinoma: A Multicenter Study by the Turkish Oncology Group (TOG)
2025
·
Ali Kalem
, Tulay Kus
, et al.
·
Journal of Clinical Medicine
·
1
PDF
Comparative efficacy of adjuvant FOLFOX vs. FLOT following neoadjuvant FLOT in patients with locally advanced gastric cancer
2025
·
FURKAN CEYLAN
, DİDEM ŞENER DEDE
, et al.
·
TURKISH JOURNAL OF MEDICAL SCIENCES
·
1
Prognostic significance of pretreatment clinical and laboratory features in patients with ovarian cancer receiving neoadjuvant chemotherapy
2024
·
Serhat Sekmek
, Dogan Bayram
, et al.
·
Oncology in Clinical Practice
·
1
PDF
Comparative Prognostic Performance of Liver Function Scores in Unresectable Hepatocellular Carcinoma Treated with First-Line Sorafenib
2026
·
Safa Can Efil
, Mehmet Akif Parlar
, et al.
·
Uludağ Üniversitesi Tıp Fakültesi Dergisi
PDF
Resection and pathological response after neoadjuvant nivolumab plus chemotherapy for lung cancer in a Turkish Oncology Group (TOG) real-world study
2026
·
Erdem Sünger
, Bahadır Köylü
, et al.
·
Research Square
PDF
Association Between ABO Blood Group and Survival Outcomes in Advanced NSCLC Treated with Immune Checkpoint Inhibitors
2026
·
Hilal Karakaş
, Safa Can Efil
, et al.
·
Current Oncology
Feasibility and Prognostic Value of an Ovarian NAR-like Score in Advanced Ovarian Cancer Treated with Neoadjuvant Chemotherapy and Interval Debulking Surgery
2026
·
Yeşim Özkaya Uçar
, Arife Ebru Kuzu
, et al.
·
Journal of Clinical Medicine
Prognostic impact of the Gustave Roussy Immune score in metastatic renal cell carcinoma treated with first-line immunotherapy-based combinations: results from the Turkish Oncology Group Kidney Cancer Consortium (TKCC)
2026
·
Aysun Fatma Akkuş
, Hatice Bölek
, et al.
·
BMC Cancer
Nutritional Indexes and Their Variations as Predictors of Atezolizumab Plus Chemotherapy Efficacy in Extensive-Stage Small Cell Lung Cancer: A Turkish Oncology Group Study
2026
·
Nazım C. Demircan
, Melek Özdemir
, et al.
·
Journal of Immunotherapy
Show more works
View as search
Works count:
38
Citation count:
69
H-index:
4
I10-index:
1
Year
Topic
Type